Cork County on the Rise: Big pharma feels at home in Cork

Irish Examiner | November 14, 2019

In 1969, when global biopharmaceutical company Pfizer located in Ringaskiddy, Cork was a very different place. Verolme, the Dutch-owned shipyard in Rushbrooke, was busy making ships, some of them patrol and fisheries vessels for the State. For generations, workers at the Sunbeam factory in Blackpool had been making textiles. On the banks of the Lee, Ford, or Ford’s as it was known locally, operated an assembly plant that made cars and tractors for places as far away as Argentina. If they needed tyres, Dunlop was only down the road. In the 50 years since, all of these companies have disappeared except Pfizer. Ringaskiddy was Pfizer’s first Irish location. Since then, the company has expanded to six sites in the country, including in Little Island. From an initial investment of €10m in 1969, Pfizer’s investment in Ireland is now €8bn, with a €2bn contribution annually to the economy. Pfizer has a 3,700-strong workforce, making it one of the country’s largest employers.

Spotlight

South Australia stands to become a national and global centre of excellence in the advancement of medicinal cannabis cultivation, manufacturing,


Other News
BUSINESS INSIGHTS, PHARMA TECH

MTTI Receives Chinese Patent for EVATHERA Technology

Molecular Targeting Technologies, Inc. | December 07, 2022

Molecular Targeting Technologies, Inc. announces the issuance of Chinese Patent CN109153641B covering MTTI’s lead radiotherapeutic product, EBTATE™ and others in its EvaThera™ platform. Approval of “Chemical conjugates of Evans blue derivatives and their use as radiotherapeutic and imaging agents” follows issued patents in the US, Europe, Singapore, and Japan this past year. EBTATE is a new generation of peptide receptor radiotherapeutic drug that has demonstrated potential clinical superiority over standard of care. It selectively targets and binds to somatostatin receptor 2 on neuroendocrine and other tumors, which are then killed by the radionuclide. EvaThera platform products were designed to bind to serum albumin, due to the Evans blue moiety, extending in vivo residence time, enabling lower, less frequent dosing of the radiopharmaceutical and reducing risk of renal injury vs. the current standard of care. Our recent 3-year follow-up report on a 30-patient, ex-US, EBTATE study showed stable disease with progression-free survival of 43 months after three cycles of EBTATE. EBTATE treatment is effective and less toxic for neuroendocrine tumor patients. * “This complements our IP portfolio, further protecting our EvaThera platform.” He added, “We’re continuing to bolster our position in radiotheranostics with planned clinical trials of our two platform products in multiple indications.” Chris Pak, MTTI’s President & CEO About Molecular Targeting Technologies, Inc. Molecular Targeting Technologies, Inc., is a privately held, rapidly growing, well financed, clinical-stage biotech company developing next-generation targeted radiotherapeutics and diagnostics for rare cancers. We are committed to building value by acquiring and translating innovative imaging, radiopharmaceutical and theranostics assets to improve human health, reduce healthcare costs and reward stakeholders. MTTI expects to be orchestrating multiple clinical trials in 2023.

Read More

BUSINESS INSIGHTS, PHARMACY MARKET

Novo Nordisk & ATLATL announce winners in their joint program EntreStar

Novo Nordisk & ATLATL | December 06, 2022

Novo Nordisk Research Centre China and ATLATL jointly announce the winners of EntreStar program. Hangzhou DNano MetaBio and Modit Medicine stood out among all participants and won the awards. The two winners will be given priority access to one of ATLATL’s nation-wide facilities in China, and a prize of CNY 500K RMB each to pay for the ATLATL facilities and services. They are also entitled to mentoring by relevant experts of Novo Nordisk. There will be no strings attached for the two companies. Founded in 2022, Hangzhou DNano MetaBio Technology has been focusing on the design of nucleic acid nanocarriers with customized functions and great potential in clinical translation. The team has rich experience in nucleic acid structure design, which enables them to accurately regulate the organ-targeting ability and the on-demand drug release performance of the nanocarriers. “It’s our great honour to participate in EntreStar. We look forward to exploring collaboration opportunities with the community. Meanwhile, it is very much appreciated that we can receive guidance and help from Novo Nordisk’s experts in relevant fields, so that our company can develop in a healthy way.” Dr. Baoquan DING, President & Chief Scientist of DNano expressed his hopes in the award ceremony, Modit Medicine Inc., founded in 2022, is a biotech company focusing on RNA editing and therapeutics. The company owns cutting-edge and propriety RNA modification and editing methodologies and is devoted to the development of novel platform technologies. Instead of manipulating DNA sequences, technologies of Modit Medicine Inc. correct genetic errors at the RNA level, thereby providing opportunities for safe, efficacious and innovative therapeutics to treat human rare diseases, cancers, etc. Dr. Chengqi YI, Founder of Modit Medicine and Boya Professor of Peking University, commented on his participation, “By participating in the EntreStar program, Modit Medicine Inc. hopes to learn from global pharma about their insights on technology platform and marketing strategies in gene therapy, as well as to seek and form potential collaborations with Novo Nordisk. We also appreciate advice and suggestions from ATLATL about useful tips for start-up companies to connect with government and industry.” Dr. Dan HAN, President of NNRCC, shared her remarks: “We see great potential in the novel concepts proposed by DNano and Modit. By leveraging knowledge and experiences in our global organisation, we hope that Novo Nordisk can help pushing their research projects forward more effectively. As a Novo Nordisk affiliate in China, we partner with brilliant minds via INNOVO® program to facilitate translational research, with EntreStar initiative as its latest addition.” Dr. Pengcheng ZHU, Founder of ATLATL Innovation Center, commented on the role ATLATL plays: “It is my greatest pleasure to help make the EntreStar winners thrive at ATLATL’s platform, with access to global resources, such as our partners like Novo Nordisk. The ATLATL Innovation Center is a world-class scientific hub for the life sciences. We streamline the elements of R&D to improve resource utilization, and revolutionize the traditional asset-heavy investment model into an asset-light operation model. I am looking forward to collaborating with even more leading biopharmaceuticals and bringing success to these talented people.” About Novo Nordisk Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 49,300 people in 80 countries and markets its products in around 170 countries. Novo Nordisk Research Centre China founded in 1997, takes pride in being the first research centre established by a multinational pharmaceutical company in China. With a focus on protein and peptide therapeutics, NNRCC has full capabilities and rich experiences in drug discovery research. About ATLATL The ATLATL Innovation Center is a world-class scientific hub for global life sciences. ATLATL streamlines the elements of R&D to improve resource utilization and revolutionizes the traditional asset-heavy investment model into an asset-light operation model. This much more time and cost-efficient model originated in Boston and continues to be optimized from 2017 onwards in China. ATLATL provides not only state-of-the-art facilities and professional operational management but also many R&D platforms staffed with scientists and project managers specializing in various fields. By collaborating with leading biopharma ATLATL integrates global resources to stimulate innovative developments. ATLATL currently has R&D platforms in Beijing, Shanghai, Suzhou, etc., leveraging the uniqueness of each site to help innovators quickly reach the next milestone.

Read More

PHARMACY MARKET, PHARMA TECH

MTTI Obtains FDA Allowance of Investigational New Drug (IND) for Hürthle Cell Thyroid Cancer

Molecular Targeting Technologies, Inc | December 09, 2022

Molecular Targeting Technologies, Inc. a clinical stage radiopharmaceutical therapy company focused on therapies for rare diseases, announced today the allowance of an Investigational New Drug application by the U.S. Food and Drug Administration. It is now waiting for Institutional Review Board approval. Once approved by IRB, it will enable a Phase I/II clinical study of the Safety, Dosimetry and Efficacy of EBTATE in adult patients with metastatic, radioactive iodine non-responsive Hürthle cell thyroid cancer.” EBTATE is a new generation of peptide receptor radiotherapeutic drug that has demonstrated potential clinical superiority over standard of care. It selectively binds to somatostatin receptor 2 on neuroendocrine and other tumors, which are then killed by the radionuclide. EvaThera platform products were designed to bind to serum albumin, due to the Evans blue moiety, extending in vivo residence time, enabling lower, less frequent dosing of the radiopharmaceutical and reducing risk of renal injury vs. the current standard of care. Dr. Joanna Klubo-Gwiezdzinska, MD, Ph.D, MHSc, acting section chief of Thyroid Tumors and Functional Thyroid Disorders in the National Institute of Diabetes and Digestive and Kidney Diseases, part of the National Institutes of Health (NIH) and study author commented: “Hürthle cell thyroid cancer, which currently lacks effective treatment options, is characterized by a particularly high expression of SSTR2*. With this phase I/II clinical trial, we hope to implement individualized dosimetry-based dosing for each patient with Hürthle cell thyroid cancer that spread outside of the thyroid gland and analyze how much of an active agent is being accumulated in the tumor tissue to establish a threshold associated with the best efficacy and safety.” “The clearance of our IND is an important milestone for MTTI. Having solidified our clinical trial preparedness and manufacturing readiness, we are well-positioned to advance EBTATE to target Hürthle cell thyroid cancer.” Dr. Chris Pak, President & CEO of MTTI About Molecular Targeting Technologies, Inc. (MTTI) Molecular Targeting Technologies, Inc., is a privately held, rapidly growing, well financed, clinical-stage biotech company developing next-generation targeted radiotherapeutics and diagnostics for rare cancers. Evathera platform technology product has shown application for glioblastoma multiforme (GBM) cancer patients overexpressing integrin. MTTI is committed to building value by acquiring and translating innovative imaging, radiopharmaceutical and theranostics assets to improve human health, reduce healthcare costs and reward stakeholders. MTTI expects to be orchestrating multiple clinical trials in 2023. The content in this release is the sole responsibility of the authors and does not necessarily represent the official views or imply endorsement of the National Institutes of Health.

Read More

PHARMACY MARKET

A novel azapeptide editing method provides potential for new drug development, Feinstein Institutes research shows

Feinstein Institutes | November 29, 2022

Peptides, short sections of proteins made up of chains of amino acids, are an important area of new drug development due to their potential for increased specificity and fewer side effects. Their main drawback is the rapid degradation by the body’s own enzymes, which has led to the need to develop longer-lasting peptide alternatives. Azapeptides are one type of peptide alternative that has shown great potential as therapeutics, exemplified by the HIV drug, Atazanavir. A new paper published in the journal Nature Communications by researchers at The Feinstein Institutes for Medical Research details proprietary reagents and methods that can selectively replace only those amino acids known to be targeted by enzymes with more stable versions to create azapeptides. The paper, authored by Yousef Al-Abed, PhD, co-director of the Institute of Bioelectronic Medicine at the Feinstein Institutes, describes the proprietary building blocks and method used to conduct systematic and robust peptide editing, replacing targeted amino acids with aza-amino acids to form more stable and efficient azapeptides. The azapeptides created could expedite the novel therapies to treat many diseases and conditions, including metabolic disease, influenza, pulmonary arterial hypertension, Crohn’s disease, arthritis, and irritable bowel diseases, among others. The paper, titled “Thiocarbazate building blocks enable the construction of azapeptides for rapid development of therapeutic candidates,” provides multiple examples of azapeptide construction, screening, and selection using a known peptide inhibitor of inflammation and bradykinin. “Peptides as drug candidates are easy to discover yet difficult to develop as final drugs because of their fast degradation in our body. A technology that circumvents these problems inherent to native peptides will change the future landscape of drug discovery. Our technology provides a platform of tools that enable minimal modification of any peptide at highly prone degradation sites, thereby increasing its life span in our body, allowing it more time to find its target and neutralize it.” Dr. Al-Abed Through peptide editing, going from peptide to azapeptide, using methods that Dr. Al-Abed and his team detail in the new paper, scientists can create potential therapies that have enhanced characteristics compared to natural peptides, like longer stabilities in a more efficient manner. Dr. Al-Abed and his team have precisely engineered thiocarbazates (a novel functional group) in the proprietary process to achieve an almost universal and more efficient means to selectively replace amino acids in a peptide chain. “Peptide drugs are a crucial resource for patients and the global pharmaceutical industry,” said Kevin J. Tracey, MD, president and CEO of the Feinstein Institutes and Karches Family Distinguished Chair in Medical Research. “Dr. Al-Abed and his team invented a fully automated chemical strategy using novel chemistry to make new peptide drugs which is an important new avenue for peptide drug discovery.” About the Feinstein Institutes The Feinstein Institutes for Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

Read More